PB-718 vs Zabopegdutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/glucagon receptor (dual) · full Obesity pipeline
PB-718
Developed by PegBio
NCT06147544 · Phase 1/2 · completed
The study randomized 36 participants to PB-718 or matched placebo and masked both participants and investigators, but its small sample and safety-focused primary endpoint make it a limited trial for judging clinical benefit. No primary-endpoint results have been posted, so whether the treatment-emergent adverse-event comparison was favorable cannot be determined. Its registered primary outcome on ClinicalTrials.gov is "Incidence of Treatment-Emergent Adverse Events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
No aligned efficacy figure on record for this race.
Zabopegdutide
Developed by D&D Pharmatech and partners
NCT04812262 · Phase 1 · completed
This Phase 1 study randomized overweight or obese adults with type 2 diabetes and fatty liver disease to DD01 or placebo in sequential single and multiple ascending-dose cohorts, with quadruple blinding and 255 participants in total. All of its registered primary endpoints measured safety and tolerability, so the trial made no formal efficacy test, and no results were posted on the registry. The sponsor announced a reduction in liver fat measured by MRI-PDFF in the high-dose group (p < 0.0001 versus placebo), but that outcome was not a registered primary endpoint and the figure comes from a company press release.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Number of participants with treatment-related adverse events and serious adverse events (Part A - 43 days); Number of participants with treatment-related adverse events and serious adverse events (TEAEs) (Part B - 57 days); Number of participants with clinically significant abnormalities in clinical laboratory values (Part A - 43 days); Number of participants with clinically significant abnormalities in clinical laboratory values (Part B - 57 days); Number of participants with clinically significant abnormalities in physical examinations (Part A - 43 days); Number of participants with clinically significant abnormalities in physical examinations (Part B - 57 days); Number of participants with clinically significant abnormalities in vital signs (Part A - 43 days); Number of participants with clinically significant abnormalities in vital signs (Part B - 57 days); Blood Pressure assessed by 24-hour ambulatory blood pressure monitoring (ABPM) (Part A - 43 days); Blood Pressure assessed by 24-hour ambulatory blood pressure monitoring (ABPM) (Part B - 57 days); Heart Rate assessed by 24-hour ambulatory electrocardiography monitoring reader) (Part A - 43 days); Heart Rate assessed by 24-hour ambulatory electrocardiography monitoring reader) (Part B - 57 days); Number of participants with clinically significant abnormalities in 12-lead ECGs (Part A - 43 days); Number of participants with clinically significant abnormalities in 12-lead ECGs (Part B - 57 days): Randomized, double-blind, placebo-controlled single and multiple ascending dose study at four US clinical sites: following only 4 weeks of treatment, all subjects in the high dose group achieved at least a 40% reduction in liver fat, with a mean reduction of more than 50% measured by MRI-PDFF (p < 0.0001 versus placebo). (not_applicable)
Result source: NCT04812262
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | PB-718 | Zabopegdutide |
|---|---|---|
| Body weight, % change | —Not reported | —Not reported |
| Weight loss of 5% or more | —Not reported | —Not reported |
| Weight loss of 10% or more | —Not reported | —Not reported |
| Waist circumference, change (cm) | —Not reported | —Not reported |
Body weight, % change
- PB-718
- —Not reported
- Zabopegdutide
- —Not reported
Weight loss of 5% or more
- PB-718
- —Not reported
- Zabopegdutide
- —Not reported
Weight loss of 10% or more
- PB-718
- —Not reported
- Zabopegdutide
- —Not reported
Waist circumference, change (cm)
- PB-718
- —Not reported
- Zabopegdutide
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
PB-718: no structured comparison results are available for Obesity.
Zabopegdutide: no structured comparison results are available for Obesity.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: PB-718's landscape · Zabopegdutide's landscape